학술논문
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
Document Type
Article
Author
Kolinsky, M.P.; Rescigno, P.; Bianchini, D.; Zafeiriou, Z.; Mehra, N.; Mateo, J.; Michalarea, V.; Riisnaes, R.; Crespo, M.; Figueiredo, I.; Miranda, S.; Nava Rodrigues, D.; Flohr, P.; Tunariu, N.; Banerji, U.; Ruddle, R.; Sharp, A.; Welti, J.; Lambros, M.; Carreira, S.; Raynaud, F.I.; Swales, K.E.; Plymate, S.; Luo, J.; Tovey, H.; Porta, N.; Slade, R.; Leonard, L.; Hall, E.; de Bono, J.S.
Source
In Annals of Oncology May 2020 31(5):619-625
Subject
Language
ISSN
0923-7534